<乌鸦传媒>Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
<乌鸦传媒>R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<乌鸦传媒>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<乌鸦传媒>尾-Thalassemia Patients Go Transfusion-Free With Gene Therapy Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
<乌鸦传媒>R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<乌鸦传媒>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<乌鸦传媒>Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
<乌鸦传媒>Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
<乌鸦传媒>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<乌鸦传媒>Upfront IDH1 Inhibitor Triples Survival in Older AML Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<乌鸦传媒>Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease Odronextamab, epcoritamab surpass 90% response threshold in early trials Dec 11, 2020
<乌鸦传媒>Chemo-Free Combo Boosts PFS in First-Line CLL PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
<乌鸦传媒>Novel Agent Active in Refractory CML Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
<乌鸦传媒>Gene Therapy Stops Bleeding in Hemophilia Single injection had durable effectiveness, study showed Dec 08, 2020
<乌鸦传媒>Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL DFS at 1 year reaches 95% in patients with undetectable MRD Dec 06, 2020
<乌鸦传媒>CRISPR-Based Tx Offers Hope in Tough-to-Treat Blood Disorders Success with investigational use of gene editing in sickle cell disease, beta-thalassemia Dec 06, 2020
<乌鸦传媒>Blood Cancers and COVID-19: 'A Medically Vulnerable' Group Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
<乌鸦传媒>JAK Inhibitor Wins in Second-Line Chronic GVHD Twice as many patients achieved a response at week 24 Dec 05, 2020
<乌鸦传媒>Sickle Cell Disease Tied to Worse COVID-19 Outcomes Black patients seem to be at higher risk for certain COVID-19 complications, death Dec 05, 2020
<乌鸦传媒>Three-Drug Regimen Reduces Myeloma Treatment Burden Efficacy maintained with addition of SQ daratumumab to pomalidomide, dexamethasone Dec 04, 2020
<乌鸦传媒>Survival Bump With Oral AML Maintenance Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients Dec 10, 2019
<乌鸦传媒>Study: Adding Aspirin to DOAC? Better Have a Good Reason Combination tied to marked increase in bleeding risk Dec 09, 2019
<乌鸦传媒>'Off-the-Shelf' Therapy Active After CAR T-Cell Failure Bispecific antibody mosunetuzumab targets CD3, CD20; needs no ex vivo T-cell processing Dec 07, 2019
<乌鸦传媒>Study Bolsters Case for Novel Xarelto Formulation for Kids Pharmacokinetic data indicate appropriate dosing schemes across wide range of weight categories Dec 07, 2019
<乌鸦传媒>Cancer-VTE Trial Falls Short High dropout rate undermines rivaroxaban prophylaxis trial Dec 05, 2018
<乌鸦传媒>Chemo-Free Tx Tops Best Option in Younger CLL Patients Improved overall survival and safety with ibrutinib-based therapy Dec 04, 2018
<乌鸦传媒>Combination Regimen Extends PFS in Myeloma Large benefit but relevance of comparator questioned Dec 04, 2018
<乌鸦传媒>$2 Test Could Transform Sickle Cell Dx in Africa May have applications in high-income countries as well Dec 04, 2018
<乌鸦传媒>ASH Offers Early Look at Updated SCD Guidelines Experts formulated >50 recommendations on sickle cell disease Dec 03, 2018
<乌鸦传媒>Add-On Drugs Could Boost Efficacy, Tolerability of CAR T-Cell Therapies Studies test addition of targeted agents, immunotherapy Dec 03, 2018
<乌鸦传媒>Novel Therapies Offer Hope in Sickle Cell Disease Studies explore possibility of parental donor; boosting fetal hemoglobin production Dec 02, 2018
<乌鸦传媒>CAR T-Cell Responses Prove Durable in ALL, DLBCL Two studies demonstrate long-term control in relapsed/refractory disease Dec 01, 2018
<乌鸦传媒>Cutting Chemo Cycles Feasible in Younger DLBCL Patients Patients, ages 18-60, fare well with four cycles of CHOP instead of six Dec 01, 2018
<乌鸦传媒>Ibrutinib Alone Wins in Older CLL Patients Adding rituximab offered no added benefit Dec 01, 2018
<乌鸦传媒>Sneak Peek at Practice-Changing Research From ASH 2018 "Big trials, big results," plus sickle cell disease and CAR T-cell therapies Nov 30, 2018
<乌鸦传媒>Mixed Results with Regimens for Older AML Patients Positive data with venetoclax, liposomal cytarabine-daunorubicin Dec 14, 2017
<乌鸦传媒>Amyloidosis Treatments Miss the Heart of the Problem Only modest improvement in end organ function Dec 07, 2016
<乌鸦传媒>Bangladesh-Boston Collaborate on ASCT Center Two dozen patients undergo successful stem cell transplant in Dhaka Dec 05, 2016
<乌鸦传媒>Can Patients With Stable CML Stop Drug Therapy? Studies examine TKI cessation and dose reduction Dec 04, 2016
<乌鸦传媒>Survival Boost With Liposomal Tx in Older AML Patients Agent may also provide a bridge to successful transplant Dec 04, 2016
